IL-1ra缓释系统防治后发性白内障的实验研究  

Experimental study on prevention of after cataract by IL-1ra drug delivery system

作　　者：刘平[1] 陈志杰[1] 郝静[1] 李志坚[1] 高维奇[1] 

机构地区：[1]哈尔滨医科大学附属第一医院眼科医院 [2]哈尔滨医科大学附属第一医院眼科医院

出　　处：《眼科新进展》2008年第8期561-564,共4页Recent Advances in Ophthalmology

基　　金：黑龙江省海外归国基金资助(编号:1151hz0351);黑龙江省卫生厅基金资助(编号:2005-141)~~

摘　　要：目的探讨白介素-1受体拮抗剂(interleukin 1 antagonist,IL-1ra)抑制后发性白内障的有效性和其缓释系统的可行性。方法将30只(30眼)行晶状体囊外摘出术后日本大耳白兔随机平均分为A组(空白对照组)、B组(术中囊袋内植入空白缓释系统)和C组(术中囊袋内植入IL-1ra缓释系统)。术后8周对3组兔眼进行裂隙灯显微镜、角膜内皮镜和组织病理学及电镜检查,并检测房水IL-1的浓度。结果术后12周,A、B及C组发生晶状体后囊膜混浊的眼数分别为10眼、10眼及3眼,差异有统计学意义(P<0.05);术后1个月,各组兔眼角膜内皮细胞数与术前比较均有显著统计学意义(P<0.05),而术前及术后C组与A组和B组比较均无显著统计学意义(P>0.05);术后1d、3d、7d、14d、28 d、56d,C组房水中IL-1的含量与A组和B组间存在显著统计学意义(P=0.000),术后第1、3、7、14、28、56天,A组和B组比较无显著统计学意义(P>0.05);光镜和电镜下C组兔眼晶状体后囊表面几乎无或只有散在的晶状体上皮细胞及纤维蛋白黏附未发现眼内毒性反应。结论后房内植入IL-1ra缓释系统,可明显抑制房水中的IL-1浓度,有效抑制后发性白内障的发生;该方法毒副作用小,是一种安全、有效的给药方式。Objective To evaluate the validity of interleukin 1 antagonist （IL-1ra） on the prevention of after cataract and the feasibility of its drug delivery system （DDS）. Methods Thirty Japanese rabbits （ 30 eyes ）, which had been received extracapsular cataract extraction, were randomly divided into 3 groups,control group（ Group A） ,capsular bag implantation of carrier DDS with- out IL-lra（ Group B） or with IL-lra DDS （ Group C）.All eyes were examined by slit-lamp microscopy, corneal epithelial microscope, histopathology and light microscope at 8 weeks after operation. The concentration of IL-1ra in aqueous humor was measured. Results In the 12th week after the operation,the number of eyes developed posterior capsule opacification （PCO） was 10,10 and 3 in Group A,B and C,respectively;Statistical study showed significant difference（P 〈 0. 05） ;There was statistical difference in the number of corneal endothelial cells of each group between before operation and 1 month after operation（ P 〈0. 05） ; However, there was no significant difference between Group C and Group A or B after and before operation（ P 〉 0.05 ） ; There was significant difference with the concentration of IL-1 in aqueous humor between Group C and Group A or B at 1 day,3 days,7 days, 14 days ,28 days and 56 days al^r operation（ P =0. 000） ,while no significant difference was found between Group A and Group B（ P 〉 0. 05 ）. No or only sporadic lens epithelial cells and fibrin sticking were found at posterior lens capsule of Group C by light and electron microscope. There was no toxic effect on corneal endothelial cells. Conclusion The implantation of IL-1ra DDS into in vivo capsular bag can effectively inhibit the rise of IL-1 in aqueous humor and the occurrence of secondary cataract. With few toxic and side effect, this potential therapy maybe demonstrated to be safe and effective against after cataract. [ Rec Adv Ophthalmol 2008 ;28（8） ：561-564]

关 键 词：IL-1受体拮抗剂 缓释系统 后发性白内障 

分 类 号：R776.1[医药卫生—眼科]